Another Executive Suite Change at Nanogen as Ludvigson Replaces Huebner | GenomeWeb

Nanogen last week announced that David Ludvigson, its executive vice president and chief financial officer, has replaced Bruce Huebner as president and chief operating officer. Ludvigson will report to Howard Birndorf, founder, chief executive officer, and chairman of the company, which is developing an electronic microarray platform for diagnostic applications.

Huebner stepped down to pursue other interests, but will stay at the San Diego-based company for several months in a transition capacity, the company said in a statement.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.